Department of Paediatric Oncology Great Ormond Street Hospital, UCL Institute of Child Health, NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK.
Paediatric Residency Program, University of Foggia, Foggia, Italy.
Pediatr Nephrol. 2022 Apr;37(4):821-832. doi: 10.1007/s00467-021-05125-5. Epub 2021 Oct 4.
Wilms tumour (WT) survivors, especially patients with associated syndromes or genitourinary anomalies due to constitutional WT1 pathogenic variant, have increased risk of kidney failure. We describe the long-term kidney function in children with WT and WT1 pathogenic variant to inform the surgical strategy and oncological management of such complex children.
Retrospective analysis of patients with WT and constitutional WT1 pathogenic variant treated at a single centre between 1993 and 2016, reviewing genotype, phenotype, tumour histology, laterality, treatment, patient survival, and kidney outcome.
We identified 25 patients (60% male, median age at diagnosis 14 months, range 4-74 months) with WT1 deletion (4), missense (2), nonsense (8), frameshift (7), or splice site (4) pathogenic variant. Thirteen (52%) had bilateral disease, 3 (12%) had WT-aniridia, 1 had incomplete Denys-Drash syndrome, 11 (44%) had genitourinary malformation, and 10 (40%) had no phenotypic anomalies. Patient survival was 100% and 3 patients were in remission after relapse at median follow-up of 9 years. Seven patients (28%) commenced chronic dialysis of which 3 were after bilateral nephrectomies. The overall kidney survival for this cohort as mean time to start of dialysis was 13.38 years (95% CI: 10.3-16.4), where 7 patients experienced kidney failure at a median of 5.6 years. All of these 7 patients were subsequently transplanted. In addition, 2 patients have stage III and stage IV chronic kidney disease and 12 patients have albuminuria and/or treatment with ACE inhibitors. Four patients (3 frameshift; 1 WT1 deletion) had normal blood pressure and kidney function without proteinuria at follow-up from 1.5 to 12 years.
Despite the known high risk of kidney disease in patients with WT and constitutional WT1 pathogenic variant, nearly two-thirds of patients had sustained native kidney function, suggesting that nephron-sparing surgery (NSS) should be attempted when possible without compromising oncological risk. Larger international studies are needed for accurate assessment of WT1genotype-kidney function phenotype correlation.
Wilms 瘤(WT)幸存者,尤其是由于 WT1 致病性变异引起的相关综合征或泌尿生殖系统异常的患者,发生肾衰竭的风险增加。我们描述了患有 WT 和 WT1 致病性变异的儿童的长期肾功能,以告知此类复杂儿童的手术策略和肿瘤学管理。
对 1993 年至 2016 年期间在一家中心接受治疗的患有 WT 和 WT1 致病性变异的患者进行回顾性分析,回顾分析基因型、表型、肿瘤组织学、侧别、治疗、患者生存和肾脏结局。
我们鉴定了 25 例(60%为男性,中位诊断年龄为 14 个月,范围为 4-74 个月)WT1 缺失(4)、错义(2)、无义(8)、移码(7)或剪接位点(4)致病性变异患者。13 例(52%)为双侧疾病,3 例(12%)为 WT-无虹膜,1 例为不完全 Denys-Drash 综合征,11 例(44%)有泌尿生殖系统畸形,10 例(40%)无表型异常。患者生存率为 100%,3 例在中位随访 9 年后复发后缓解。7 例(28%)开始慢性透析,其中 3 例在双侧肾切除术后。该队列的总体肾脏生存率为开始透析的平均时间为 13.38 年(95%CI:10.3-16.4),其中 7 例患者在中位 5.6 年内发生肾衰竭。所有这 7 例患者随后均进行了移植。此外,2 例患者患有 III 期和 IV 期慢性肾脏病,12 例患者有白蛋白尿和/或使用血管紧张素转换酶抑制剂治疗。4 例患者(3 例移码;1 例 WT1 缺失)血压和肾功能正常,无蛋白尿,随访 1.5-12 年。
尽管已知 WT 和 WT1 致病性变异的患者发生肾脏疾病的风险较高,但近三分之二的患者持续保持了正常的肾脏功能,这表明在不影响肿瘤学风险的情况下,应尝试保留肾单位手术(NSS)。需要更大规模的国际研究来准确评估 WT1 基因型-肾脏功能-表型相关性。